Key result
Beta-blockers show no long-term benefit for CV death or recurrent MI in stable post-MI patients.
Why the study?
The long-term cardioprotective effect of beta-blocker treatment in stable, optimally treated myocardial infarction patients without heart failure remained unclear.
Does long-term beta-blocker treatment reduce cardiovascular death, recurrent MI, or composite cardiovascular events in stable, optimally treated MI patients without heart failure?
Population
30 177 stable, optimally treated MI patients without HF undergoing CAG or PCI
Comparison
Beta-blocker treatment vs no beta-blocker treatment
Design
Nationwide registry-based cohort study
Follow-up
3 years after MI
Authors
Loading...
May not justify routine long-term beta-blockers in stable post-MI patients without HF; challenges consensus but leaves open for RCTs.
Does long-term beta-blocker treatment reduce cardiovascular death, recurrent MI, or composite cardiovascular events in stable, optimally treated MI patients without heart failure?
Routine long-term beta-blocker therapy does not improve cardiovascular outcomes in stable patients without heart failure who are optimally treated after a myocardial infarction.
Holt et al. (2020) studied this question. Beta-blocker treatment showed no long-term effect on cardiovascular death or recurrent myocardial infarction in stable MI patients, with ARD of 0.1% and 0.2%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: